

Supplementary Material

The Impact of Disease Activity Criteria on Extending Injection Intervals in Real-world Patients with Neovascular Age-related Macular Degeneration

Bhairavi Bhatia, Sing Yue Sim, Evangelia Chalkiadaki, Georgios Koutsocheras, Luke Nicholson, Senthil Selvam, Sobha Sivaprasad, Bishwanath Pal, Josef Huemer, Pearse Keane, Robin Hamilton, Praveen J Patel, on behalf of Moorfields Medical Retina Injection Service

NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust & UCL Institute of Ophthalmology, London, United Kingdom

Correspondence details

Praveen J Patel, NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust & UCL Institute of Ophthalmology, London, United Kingdom

Email: praveen.patel1@nhs.net

Bhairavi Bhatia, Department of Ophthalmology, Addenbrookes Hospital, Cambridge, CB2 0QQ, United Kingdom

Email: bhairavi.bhatia1@nhs.net

Supplementary figure 1:

Examples of OCT macula scans with fluid present that do not fulfil the clinical trials disease activity criteria but are classed as active in clinical practice

Figure S1a: New subretinal fluid within the central subfield not causing significant increase in CST




Figure S1b: Increase in subretinal fluid away from the central subfield

